Join us for a Vor-sponsored webinar to learn about telitacicept, an investigational treatment being studied for patients with gMG. You will discover: How telitacicept works in a different way from other current therapies by targeting key immune signalling proteins that play a part in the production of MG-causing antibodies. Available data from clinical studies of telitacicept in patients with gMG. Details around an ongoing, currently enrolling global clinical trial of telitacicept in patients with gMG that includes study sites in the US.
Learn more